SCHEMBL26206322

SCHEMBL26206322

C[C@@H](CCC(N)=O)COCc1ccc(CCCCC(=O)O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ S1PR2 O95136 1/20 0.42
▸ S1PR1 P21453 1/20 0.42
▸ S1PR3 Q99500 1/20 0.42
▸ FFAR4 Q5NUL3 2/20 0.41
▸ HSD17B10 Q99714 1/20 0.40
▸ ITGB3 P05106 1/20 0.40
▸ ITGA2B P08514 1/20 0.40
▸ TBXAS1 P24557 1/20 0.39
▸ HDAC3 O15379 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ ADRA1A P35348 1/20 0.39
▸ HDAC4 P56524 1/20 0.39
▸ SLC6A3 Q01959 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ HDAC7 Q8WUI4 1/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ HDAC10 Q969S8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26206075 0.88 ADRB2 (0.37) ITGB3ITGA2B
SCHEMBL26206388 0.84 MAPT (0.50) MAPTRXFP1S1PR2S1PR1S1PR3
SCHEMBL26206459 0.84 FFAR1 (0.47) MAPTRXFP1S1PR2S1PR1S1PR3
SCHEMBL26206347 0.84 FFAR1 (0.47) S1PR2S1PR1S1PR3HSD17B10
SCHEMBL26205610 0.80 EPHX1 (0.42) MAPTFFAR4
SCHEMBL22527034 0.78 PPARA (0.47) ITGB3ITGA2B
SCHEMBL7179932 0.77 FOLH1 (0.52) MAPTRXFP1HDAC3MAPK1ADRA1A
SCHEMBL26206481 0.77 TSHR (0.44) MAPTRXFP1S1PR2S1PR1S1PR3
SCHEMBL5870182 0.77 FOLH1 (0.58) —
SCHEMBL26206355 0.76 ALDH1A1 (0.44) MAPTFFAR4HSD17B10SLC6A3HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746120-B2 Stat degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-09-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11746120-B2 Stat degraders and uses thereof STAT4, STAT1, STAT3 MAPT 3167/4885RXFP1 2746/4885S1PR2 3085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback